{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:31:12Z","timestamp":1773423072426,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>This study examined the accuracy of radioactive seed localization (RSL) of lymph nodes (LNs) following neoadjuvant chemotherapy (NAC) for invasive breast carcinoma, recorded pathologic features of LNs following NAC, evaluated concordance of response between breast and LNs, and identified clinicopathologic factors associated with higher risk of residual lymph node involvement.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinical records, imaging, and pathology reports and slides were retrospectively reviewed for 174 breast cancer patients who received NAC. Chi-square and Fisher\u2019s exact tests were used to compare differences in risk of residual lymph node disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Retrieval of biopsied pre-therapy positive LN was confirmed in 86\/93 (88%) cases overall, and in 75\/77 (97%) of cases utilizing RSL. Biopsy clip site was the best pathologic feature to confirm retrieval of a biopsied lymph node. Pre-therapy clinical N stage\u2009&gt;\u20090, positive pre-therapy lymph node biopsy, estrogen and progesterone receptor positivity, Ki67\u2009&lt;\u200950%, HR\u2009+\u2009\/HER2\u2212 tumors, and residual breast disease had higher likelihood of residual lymph node disease after NAC (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>RSL-guided LN excision improves retrieval of previously biopsied LNs following NAC. The pathologist can use histologic features to confirm retrieval of targeted LNs, and tumor characteristics can be used to predict a higher risk of residual LN involvement.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-023-06983-3","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T03:26:22Z","timestamp":1686194782000},"page":"363-373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Response in axillary lymph nodes to neoadjuvant chemotherapy for breast cancers: correlation with breast response, pathologic features, and accuracy of radioactive seed localization"],"prefix":"10.1007","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5965-8294","authenticated-orcid":false,"given":"Beth Z.","family":"Clark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendie A.","family":"Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla","family":"McAuliffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"issue":"5","key":"6983_CR1","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1200\/JCO.2002.20.5.1304","volume":"20","author":"R Rouzier","year":"2002","unstructured":"Rouzier R, Extra JM, Klijanienko J et al (2002) Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20(5):1304\u20131310","journal-title":"J Clin Oncol"},{"issue":"2","key":"6983_CR2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","volume":"17","author":"HM Kuerer","year":"1999","unstructured":"Kuerer HM, Newman LA, Smith TL et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17(2):460\u2013469","journal-title":"J Clin Oncol"},{"issue":"6","key":"6983_CR3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1245\/ASO.2006.07.024","volume":"13","author":"PF Escobar","year":"2006","unstructured":"Escobar PF, Patrick RJ, Rybicki LA, Hicks D, Weng DE, Crowe JP (2006) Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer. Ann Surg Oncol 13(6):783\u2013787","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"6983_CR4","first-page":"230","volume":"4","author":"HM Kuerer","year":"1998","unstructured":"Kuerer HM, Newman LA, Buzdar AU et al (1998) Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am 4(4):230\u2013236","journal-title":"Cancer J Sci Am"},{"issue":"36","key":"6983_CR5","doi-asserted-by":"publisher","first-page":"9304","DOI":"10.1200\/JCO.2005.02.5023","volume":"23","author":"BT Hennessy","year":"2005","unstructured":"Hennessy BT, Hortobagyi GN, Rouzier R et al (2005) Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23(36):9304\u20139311","journal-title":"J Clin Oncol"},{"issue":"15","key":"6983_CR6","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796\u20131804","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"6983_CR7","doi-asserted-by":"publisher","first-page":"S495","DOI":"10.1245\/s10434-015-4697-7","volume":"22","author":"TJ Yang","year":"2015","unstructured":"Yang TJ, Morrow M, Modi S et al (2015) The effect of molecular subtype and residual disease on locoregional recurrence in breast cancer patients treated with neoadjuvant chemotherapy and postmastectomy radiation. Ann Surg Oncol 22(Suppl 3):S495-501","journal-title":"Ann Surg Oncol"},{"issue":"28","key":"6983_CR8","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans WF, Peintinger F, Hatzis C et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414\u20134422","journal-title":"J Clin Oncol"},{"issue":"4","key":"6983_CR9","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/SLA.0000000000001375","volume":"263","author":"JC Boughey","year":"2016","unstructured":"Boughey JC, Ballman KV, Le-Petross HT et al (2016) Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0\u2013T4, N1\u2013N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg 263(4):802\u2013807","journal-title":"Ann Surg"},{"issue":"10","key":"6983_CR10","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S et al (2016) Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 34(10):1072\u20131078","journal-title":"J Clin Oncol"},{"issue":"11","key":"6983_CR11","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1245\/s10434-019-07517-2","volume":"26","author":"SM Wong","year":"2019","unstructured":"Wong SM, Almana N, Choi J et al (2019) Prognostic significance of residual axillary nodal micrometastases and isolated tumor cells after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol 26(11):3502\u20133509","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"6983_CR12","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1245\/s10434-019-07540-3","volume":"26","author":"MK Srour","year":"2019","unstructured":"Srour MK, Tseng J, Luu M, Alban RF, Giuliano AE, Chung A (2019) Patterns in the use of axillary operations for patients with node-positive breast cancer after neoadjuvant chemotherapy: a national cancer database (NCDB) analysis. Ann Surg Oncol 26(10):3305\u20133311","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"6983_CR13","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1200\/JCO.2005.05.188","volume":"23","author":"EP Mamounas","year":"2005","unstructured":"Mamounas EP, Brown A, Anderson S et al (2005) Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 23(12):2694\u20132702","journal-title":"J Clin Oncol"},{"issue":"7","key":"6983_CR14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14(7):609\u2013618","journal-title":"Lancet Oncol"},{"issue":"2","key":"6983_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10549-018-5004-7","volume":"173","author":"JM Classe","year":"2019","unstructured":"Classe JM, Loaec C, Gimbergues P et al (2019) Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat 173(2):343\u2013352","journal-title":"Breast Cancer Res Treat"},{"issue":"14","key":"6983_CR16","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310(14):1455\u20131461","journal-title":"JAMA"},{"issue":"5","key":"6983_CR17","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1245\/s10434-015-5052-8","volume":"23","author":"EJ Diego","year":"2016","unstructured":"Diego EJ, McAuliffe PF, Soran A et al (2016) Axillary staging after neoadjuvant chemotherapy for breast cancer: a pilot study combining sentinel lymph node biopsy with radioactive seed localization of pre-treatment positive axillary lymph nodes. Ann Surg Oncol 23(5):1549\u20131553","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"6983_CR18","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/cncr.10741","volume":"95","author":"ER Fisher","year":"2002","unstructured":"Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N (2002) Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95(4):681\u2013695","journal-title":"Cancer"},{"issue":"3","key":"6983_CR19","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/SLA.0000000000003126","volume":"271","author":"S Samiei","year":"2020","unstructured":"Samiei S, van Nijnatten TJA, de Munck L et al (2020) Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. Ann Surg 271(3):574\u2013580","journal-title":"Ann Surg"},{"issue":"1","key":"6983_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/00000658-199907000-00011","volume":"230","author":"HM Kuerer","year":"1999","unstructured":"Kuerer HM, Sahin AA, Hunt KK et al (1999) Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230(1):72\u201378","journal-title":"Ann Surg"},{"issue":"5","key":"6983_CR21","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1097\/SLA.0000000000002313","volume":"267","author":"HM Kuerer","year":"2018","unstructured":"Kuerer HM, Rauch GM, Krishnamurthy S et al (2018) A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy. Ann Surg 267(5):946\u2013951","journal-title":"Ann Surg"},{"issue":"7","key":"6983_CR22","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","volume":"152","author":"AB Tadros","year":"2017","unstructured":"Tadros AB, Yang WT, Krishnamurthy S et al (2017) Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg 152(7):665\u2013670","journal-title":"JAMA Surg"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06983-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-06983-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06983-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T06:32:39Z","timestamp":1687847559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-06983-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["6983"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-06983-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"assertion":[{"value":"8 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"W.A.B. discloses grant support to the Department from Koios Medical, Inc. and she is voluntary Chief Scientific Advisor to DenseBreast-info.org. Other authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Human Research Protection Office at the University of Pittsburgh, with waiver of informed consent for access of electronic health record and pathology slide review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}